The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Joe is now testing a new treatment using a nasal spray, the medication inside is called Foralumab. He is the first patient with Alzheimer's to try it. The Walsh family is hopeful. Foralumab is ...
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application (NDA) for Stapokibart to treat seasonal allergic rhinitis. The approval is ...
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...